Back to search results

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Prostate Cancer (Adenocarcinoma) · Prostate CA · Prostate Cancers · Prostate Cancer (Post Prostatectomy) · Prostate Cancer · Prostate Cancer Patients Undergoing Radical Prostatectomy · High-risk Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic, Chicago, Illinois, United States

  • Central Ohio Urology Group, Gahanna, Ohio, United States

    Contact: Study coordinator (Ronney Abaza, MD) · dublinoffice@centralohiourology.com · 614-796-2842

  • Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

    Contact: Study coordinator (Neal Shore, MD) · nshore@auclinics.com · 843-839-1679
Study leads

  • Fernando Kreutz, MD PhD

    Study Chair

    Cellvax Therapeutics Inc

View source on ClinicalTrials.gov(opens in a new tab)